


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A compound of the formula (I) below, or a pharmacologically acceptable salt thereof:



wherein:

A represents a pyrazole ring having one substituent R⁴;

R¹ represents a phenyl group, a 4-fluorophenyl group, a 3-fluorophenyl group, a 3-chlorophenyl group, a 3,4-difluorophenyl group, a 3,4,5-trifluorophenyl group, a 3-chloro-4-fluorophenyl group, a 3-difluoromethoxyphenyl group or a 3-trifluoromethylphenyl group;

R² represents an unsubstituted 4-pyridyl group, an unsubstituted 4-pyrimidinyl group, a 4-pyridyl group which is substituted at the 2-position thereof with one substituent selected from the group consisting of methoxy, amino, methylamino, benzylamino and a-methylbenzylamino, or a 4-pyrimidinyl group which is substituted at the 2-position thereof with one substituent selected from the group consisting of

R³ represents a group of formula (IIa), (IIb) or (IIc) shown below:



a bond including a dotted line represents a single bond or a double bond,

m represents 1 or 2,

R⁵ represents one substituent which is independently selected from the group consisting of a hydrogen atom, a methoxy group, a methyl group, an ethyl group, a propyl group and a phenyl group,

one of D and E represents a nitrogen atom and the other represents a group of a formula $>C(R^6)-$, wherein R^6 is a substituent selected from the group consisting of a hydrogen atom, a Substituent group α and a Substituent group β , and

B represents a, pyrrolidine ring or a pyrroline ring, and

R⁴ represents a hydrogen atom, a lower alkyl group, a halogeno lower alkyl group, or a phenyl group substituted with one or more substituents selected from the group consisting of Substituent group α , Substituent group β and Substituent group γ ,

PROVIDED THAT said substituents R^1 and R^3 are bonded to the two atoms of said cyclic group A which are adjacent to the atom of the cyclic group A to which said substituent R^2 is bonded;

Substituent group α is selected from the group consisting of hydroxyl groups, nitro groups, cyano groups, halogen atoms, lower alkoxy groups, halogeno lower alkoxy groups, lower alkylthio groups, halogeno lower alkylthio groups and groups of a formula $-NR^aR^b$, wherein R^a and R^b are the same or different from each other and each represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an aralkyl group or a lower alkylsulfonyl group, or R^a and R^b , taken together with the nitrogen atom to which they are attached, form a heterocyclyl group;

Substituent group β is selected from the group consisting of unsubstituted lower alkyl groups, unsubstituted lower alkenyl groups, unsubstituted lower alkynyl groups, aralkyl groups, cycloalkyl groups, lower alkyl groups which are substituted with one or more substituents from Substituent group α , lower alkenyl groups which are substituted with one or more substituents from Substituent group α , and lower alkynyl groups which are substituted with one or more substituents from Substituent group α ;

Substituents group γ is selected from the group consisting of oxo groups; hydroxyimino groups; lower alkoxyimino groups; lower

alkylene groups; lower alkylenedioxy groups; lower alkylsulfinyl groups; lower alkylsulfonyl groups; unsubstituted aryl groups; aryl groups which are substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β ; unsubstituted aryloxy groups; aryloxy groups which are substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β ; lower alkylidenyl groups and aralkylidenyl groups.

Claims 2 to 13. (canceled)

Claim 14. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein R^3 is a group of the formula (IIa).

Claim 15. (canceled)

Claim 16. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein m is 1.

Claims 17 to 36. (canceled)

Claim 37. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the

compound is 3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-phenyl-4-(pyridin-4-yl)-pyrazole.

Claim 38. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(3-fluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 39. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(4-fluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 40. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 41. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 42. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 43. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(3-chlorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 44. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(3,4-difluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 45. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 3-(2-ethyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole.

Claim 46. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-propyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 47. (previously presented) The compound according to Claim 1, or a pharmacologically acceptable salt thereof, selected from the group consisting of:

5-(4-fluorophenyl)-3-(2-hydroxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,

3-(2-fluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole,

3-(2,2-difluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole,


5-(4-fluorophenyl)-3-(8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)-5-(3-trifluoromethylphenyl)pyrazole,
5-(4-fluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole,
3-(4-fluorophenyl)-5-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole,
3-(4-fluorophenyl)-1-methyl-5-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
3-(4-fluorophenyl)-1-methyl-5-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
3-(4-fluorophenyl)-5-(2-hydroxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole,
3-(4-fluorophenyl)-5-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole,
5-(2-fluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)pyrazole,
5-(2,2-difluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)pyrazole,
3-(4-fluorophenyl)-1-methyl-5-(8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-4-(pyridin-4-yl)-3-(3,5,6,8a-tetrahydroindolizin-7-yl)pyrazole,
5-(4-fluorophenyl)-3-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,

5-(4-fluorophenyl)-3-(7-hydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-3-(1,2,3,5,6,7,8,8a-octahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-chlorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-3-(2-methyliden-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
3-(2-ethyliden-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-3-(2-propyliden-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-1-methyl-3-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-1-methyl-3-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-3-(2-hydroxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-3-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole,
3-(2-fluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-1-methyl-3-(8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
5-(4-fluorophenyl)-3-(2-methyl-3,5,6,8a-tetrahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole,
3-(2-ethyl-3,5,6,8a-tetrahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole,

5-(4-fluorophenyl)-3-(2-propyl-3,5,6,8a-tetrahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, and

5-(4-fluorophenyl)-3-(2-phenyl-3,5,6,8a-tetrahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.

Claim 48. (currently amended) A compound of the formula (I) below, or a pharmacologically acceptable salt thereof:




wherein:

A represents a pyrazole ring having one substituent R⁴;

R¹ represents a phenyl group, a 4-fluorophenyl group, a 3-fluorophenyl group, a 3-chlorophenyl group, a 3,4-difluorophenyl group, a 3,4,5-trifluorophenyl group, a 3-chloro-4-fluorophenyl group, a 3-difluoromethoxyphenyl group or a 3-trifluoromethoxyphenyl group;

R² represents an unsubstituted 4-pyridyl group; an unsubstituted 4-pyrimidinyl group; a 4-pyridyl group which is substituted at the 2-position thereof with one substituent selected from the group consisting of methoxy, amino, methylamino, benzylamino and α-methylbenzylamino; or a 4-pyrimidinyl group which is substituted at the 2-position thereof with one substituent selected from the group consisting of methoxy, amino, methylamino, benzylamino and α-methylbenzylamino; and

R^3 represents a group of formula (IIa), (IIb) or (IIc) shown below:



wherein

a bond including a dotted line represents a single bond or a double bond,

m represents 1 or 2,

R^5 represents one substituent which is independently selected from the group consisting of a hydrogen atom, a methoxy group, a methyl group, an ethyl group, a propyl group and a phenyl group,

one of D and E represents a nitrogen atom and the other represents a group of a formula $>C(R^6)-$, wherein R^6 is a substituent selected from the group consisting of a hydrogen atom, a Substituent group α and a Substituent group β , and

B represents a $[[a]]$ pyrrolidine ring or a pyrroline ring, and

R^4 represents a hydrogen atom; a lower alkyl group, a halogeno lower alkyl group, or a phenyl group substituted with one or more substituents selected from the group consisting of Substituent group α , Substituent group β and Substituent group γ ,

PROVIDED THAT said substituents R^1 and R^3 are bonded to the two atoms of said cyclic group A which are adjacent to the atom of the cyclic group A to which said substituent R^2 is bonded;

Substituent group α is selected from the group consisting of hydroxyl groups, nitro groups, cyano groups, halogen atoms, lower alkoxy groups, halogeno lower alkoxy groups, lower alkylthio groups, halogeno lower alkylthio groups and groups of formula $-NR^aR^b$, wherein R^a and R^b are the same or different from each other and each represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an aralkyl group or a lower alkylsulfonyl group, or R^a and R^b , taken together with the nitrogen atom to which they are attached, form a heterocyclyl group;

Substituent group β is selected from the group consisting of unsubstituted lower alkyl groups, unsubstituted lower alkenyl groups, unsubstituted lower alkynyl groups, aralkyl groups, cycloalkyl groups, lower alkyl groups which are substituted with groups from Substituent group α , lower alkenyl groups which are substituted with one or more groups from Substituent group α , and lower alkynyl which are substituted with one or more substituents which are substituted with groups from Substituent group α ;

Substituents group γ is selected from the group consisting of oxo groups; hydroxyimino groups; lower alkoxyimino groups; lower alkylene groups; lower alkylenedioxy groups; lower alkylsulfinyl groups; lower alkylsulfonyl groups; unsubstituted aryl groups; and aryl groups which are substituted with groups selected from

the group consisting of Substituent group α and Substituent group β .

Claim 49. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to any one of Claims 1, 14, 16 or 37 to 47, or a pharmacologically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

Claims 50 to 69. (canceled)

Claim 70. (previously presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is a group of formula (IIb).

Claim 71. (previously presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is a group of the formula (IIc).